House NC, Brown VE, Chen M, Yuan L, et al. Profiling the Activity of the Potent and Highly Selective CDK2 Inhibitor BLU-222 Reveals Determinants of Response in CCNE1-Aberrant Ovarian and Endometrial Tumors. Cancer Res 2025 Feb 13. doi: 10.1158/0008-5472.CAN-24-2360.
PMID: 39945650